Sep 9, 2024, 08:35
Carmine Valenza: Our contribution regarding ESR1m, endocrine-responsive metastatic breast cancer
Carmine Valenza, MPH Student at Harvard T.H. Chan School of Public Health, shared a post on X:
“Happy to share our last contribution regarding ESR1m, endocrine-responsive mBC.
Patient selection according to clinical and molecular features is the key in the post-CDK4/6i setting.
Thanks to all the coauthors!”
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? published in ScienceDirect.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08